末期肾病 (ESRD) 市场规模、份额、成长分析、按治疗、按诊断、按最终用途、按地区 - 行业预测，2025-2032 年

2023年全球末期肾病（ESRD）市场规模为1120.8亿美元，在预测期内从2024年的1267.6亿美元增长到2032年的3393.8亿美元（预计复合年增长率为13.1） 2025 年至2032 年的百分比）。

由于慢性肾臟病（CKD）盛行率的上升和医疗技术的进步，特别是低维护透析系统和人工肾臟的进步，肾衰竭市场正在经历显着增长。 CKD 是由糖尿病、高血压和生活习惯引起的，影响着世界上约 10% 的人口。中国和印度等开发中国家的老年人口尤其脆弱，末期肾病 (ESRD) 病例每年增加 5-7%。美国约有 8,000 万成年人面临 CKD 的风险，而 CKD 已被证明是导致死亡的主要原因。穿戴式人工肾臟 2.0 等创新和强大的医疗基础设施正在促进市场扩张。目前约 7,500 家透析诊所网路的扩张进一步支持了这一趋势。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 产品平臺分析
• 案例研究分析
• 专利分析
• 监管分析

按治疗分類的末期肾病 (ESRD) 市场规模

• 市场概况
• 移植
• 透析
  • 腹膜透析
  • 血液透析机
  • 穿戴式人工肾

按诊断分類的末期肾病 (ESRD) 市场规模

• 市场概况
• 验血
• 尿液检查
• 影像检查
• 其他的

以最终用途分類的末期肾病 (ESRD) 市场规模

• 市场概况
• 医院
• 透析中心
• 其他的

末期肾病（ESRD）市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• AngioDynamics, Inc.（US）
• Asahi Kasei Medical Co., Ltd.（Japan）
• B. Braun Melsungen AG（Germany）
• Baxter International, Inc.（US）
• Becton Dickinson and Company（US）
• Cantel Medical（US）
• DaVita Inc.（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• JMS Co., Ltd.（Japan）
• Medtronic Plc（Ireland）
• Nikkiso Co., Ltd.（Japan）
• Nipro Corporation（Japan）
• Teleflex Incorporated（US）
• Toray Industries Inc.（Japan）
• US Renal Care, Inc.（US）
• Pfizer Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Dr. Reddy's Laboratories Ltd.（India）
• Endo International plc（Ireland）

结论和建议

Global End-Stage Renal Disease (ESRD) Market size was valued at USD 112.08 billion in 2023 and is poised to grow from USD 126.76 billion in 2024 to USD 339.38 billion by 2032, growing at a CAGR of 13.1% during the forecast period (2025-2032).

The kidney failure market is experiencing significant growth, driven by the rising incidence of Chronic Kidney Disease (CKD) and advancements in medical technology, particularly low-maintenance dialysis systems and artificial kidneys. CKD, stemming from diabetes, hypertension, and lifestyle factors, affects roughly 10% of the global population. The elderly demographic in developing nations like China and India is particularly vulnerable, with cases of end-stage renal disease (ESRD) increasing annually by 5-7%. In the U.S., approximately 80 million adults are at risk for CKD, underscoring its status as a leading cause of mortality. Market expansion is fueled by innovations such as the Wearable Artificial Kidney 2.0 and a robust healthcare infrastructure. The growing network of dialysis clinics, now numbering around 7,500, further supports this upward trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global End-Stage Renal Disease (Esrd) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global End-Stage Renal Disease (Esrd) Market Segmental Analysis

Global End-Stage Renal Disease (ESRD) Market is segmented by treatment, diagnosis, end use and region. Based on treatment, the market is segmented into transplant and dialysis. Based on diagnosis, the market is segmented into blood test, urine test, imaging test and others. Based on end use, the market is segmented into hospitals, dialysis centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global End-Stage Renal Disease (Esrd) Market

One of the primary factors driving the global end-stage renal disease (ESRD) market is the rising incidence of chronic kidney disease (CKD), which is often linked to prevalent conditions like hypertension and diabetes. As these chronic ailments become increasingly common, a larger segment of the population is at risk of developing CKD, which can ultimately lead to ESRD. This growing patient demographic heightens the need for effective treatment modalities such as dialysis and kidney transplantation. Consequently, this heightened demand for specialized care and interventions is significantly contributing to the expansion and growth of the ESRD market on a global scale.

Restraints in the Global End-Stage Renal Disease (Esrd) Market

One significant challenge in the global End-Stage Renal Disease (ESRD) market is the restricted availability and accessibility of treatment options, particularly kidney transplantation. The demand for kidney transplants vastly overshadows the supply of compatible organs, resulting in extensive waiting lists and prolonged delays for patients in need. Furthermore, while dialysis serves as a viable treatment, it comes with its own set of obstacles, including issues related to patient adherence, high costs, and the requirement for frequent treatment sessions. These factors collectively hinder timely access to optimal care for individuals suffering from end-stage renal disease, ultimately affecting the growth of the market.

Market Trends of the Global End-Stage Renal Disease (Esrd) Market

A prominent market trend in the global end-stage renal disease (ESRD) sector is the rising prevalence of home-based dialysis treatments, which cater to patients' demands for convenience, reduced healthcare costs, and improved health outcomes. Growing preferences for modalities like peritoneal dialysis and home hemodialysis reflect a desire for increased flexibility and independence, allowing patients to undergo treatment in a familiar environment. This shift is further fueled by technological advancements, robust training initiatives, and supportive reimbursement frameworks, all of which facilitate the transition to home dialysis. Consequently, this trend is significantly propelling the growth and transformation of the ESRD market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Product Pipeline Analysis
• Case Study Analysis
• Patent Analysis
• Regulatory Analysis

Global End-Stage Renal Disease (ESRD) Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Transplant
• Dialysis
  • Peritoneal Dialysis
  • Hemodialysis
  • Wearable Artificial Kidney

Global End-Stage Renal Disease (ESRD) Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• Imaging Test
• Others

Global End-Stage Renal Disease (ESRD) Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Dialysis Centers
• Others

Global End-Stage Renal Disease (ESRD) Market Size & CAGR (2025-2032)

• North America (Treatment, Diagnosis, End Use)
  • US
  • Canada
• Europe (Treatment, Diagnosis, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Diagnosis, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Diagnosis, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Diagnosis, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AngioDynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Medical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cantel Medical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JMS Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nikkiso Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nipro Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toray Industries Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• U.S. Renal Care, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations